Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C Non 2 -3 Genotype naïve Patients Treated With a 12 Weeks Bitherapy of Peginterferon Alpha 2a-ribavirin, and Followed by a Tritherapy of Peginterferon Alpha 2a-ribavirin-amantadine for 36 Weeks

NCT00199719 is registered in ClinicalTrials.gov with University Hospital, Limoges as lead sponsor.

NCT NCT00199719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00199719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C Non 2 -3 Genotype naïve Patients Treated With a 12 Weeks Bitherapy of Peginterferon Alpha 2a-ribavirin, and Followed by a Tritherapy of Peginterferon Alpha 2a-ribavirin-amantadine for 36 Weeks
Lead sponsor
University Hospital, Limoges
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
September 30, 2006
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c